| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Third National Report on the implementation of the Cartagena Protocol on Biosafety
Record information and status
Record ID
109109
Status
Published
Date of creation
2015-10-30 12:04 UTC (protocolo.cartagena@magrama.es)
Date of publication
2015-10-30 12:04 UTC (protocolo.cartagena@magrama.es)

This document is also available in the following languages:
Origin of report
1. Country
  • Spain
Contact officer for report
Coordinates
Esther Esteban Rodrigo
Punto Focal Nacional del Protocolo de Cartagena y Punto Focal del CIISB
Ministerio de Agricultura, Alimentación y Medio Ambiente
Pº. Infanta Isabel, 1 Madrid
Madrid, España
Spain, 28071
Phone:+34 91 347 6931
Fax:+34 91 347 6703
Email:protocolo.cartagena@magrama.es
Consulted stakeholders
9. Organizations/stakeholders who were consulted or participated in the preparation of this report
ES
Comisión  Nacional de Bioseguridad
Consejo Interministerial de Organismos Modificados Genéticamente
Submission
10. Date of submission
2015-10-30
11. Time period covered by this report
Start date
2011-10-01
11. Time period covered by this report
End date
2015-10-30
Party to the Cartagena Protocol on Biosafety
Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?
  • Yes
Article 2 – General provisions
14. Has your country introduced the necessary legal, administrative and other measures for the implementation of the Protocol?
This question is relevant to indicators 1.1.1, 2.1.1, 2.1.2, and 3.1.2 of the Strategic Plan
  • A domestic regulatory framework is fully in place
15. If you indicated that a national biosafety framework exists in the above question, when did it become operational?
This question is relevant to the indicator 1.1.1 of the Strategic Plan
  • 2001 or earlier
16. Which specific instruments are in place for the implementation of your national biosafety framework?
  • One or more national biosafety laws
  • One or more national biosafety regulations
  • Other laws, regulations or guidelines that indirectly apply to biosafety
17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?
  • Yes
18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?
  • Yes
19. If you answered Yes to question 18, how many permanent staff members are in place whose functions are directly related to the national biosafety framework?
  • More than 10
20. Has your country’s biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?
  • Yes
21. Here you may provide further details on the implementation of Article 2 in your country
ES
España es un Estado Miembro de la Unión Europea y ha traspuesto a su legislación la normativa sobre organismos vivos modificados elaborada por la Unión Europea y el resto de directa aplicación, destacando la directiva 2001/18/CE y los reglamentos 1829/2003 y 1830/2003. Adicionalmente, durante el periodo que comprende el informe, se han aprobado el Reglamento de Ejecución (UE) no 503/2013 de 3 de abril de 2013 sobre las solicitudes de autorización de alimentos y piensos modificados genéticamente de conformidad con el Reglamento (CE) nº 1829/2003 del Parlamento Europeo y del Consejo y por el que se modifican los Reglamentos (CE) nº 641/2004 y (CE) nº 1981/2006, y la Directiva (UE) 2015/412 del Parlamento Europeo y del Consejo, de 11 de marzo 2015, por la que se modifica la Directiva 2001/18 /CE en lo que respecta a la posibilidad de que los Estados miembros restrinjan o prohíban el cultivo de OMG en su territorio (véase el informe nacional realizado por la Unión Europea). El marco legislativo actual se regula a través de la Ley 9/2003, de 25 de abril, por la que se establece el régimen jurídico de la utilización confinada, liberación voluntaria y comercialización de organismos modificados genéticamente y el Real Decreto 178/2004, de 30 de enero, por el que se aprueba el Reglamento general para el desarrollo y ejecución de la Ley 9/2003, el cual ha sido modificado posteriormente por el Real Decreto 191/2013, de 15 de marzo.
Adicionalmente, varios instrumentos, reales decretos, órdenes y reglamentos internos se han aprobado con el objeto de desarrollar la Ley 9/2003 y adaptarse a la realidad cambiante de la biotecnología y dar mayor visibilidad en materia de bioseguridad a la sociedad, destacando entre ellos:
- Instrumento de Ratificación del Protocolo de Cartagena sobre Seguridad de la Biotecnología del Convenio sobre la Diversidad Biológica, hecho en Montreal el 29 de enero de 2000.
- Real Decreto 367/2010, de 26 de marzo, de modificación de diversos reglamentos en el área de medio ambiente para su adaptación a la Ley 17/2009, de 23 de noviembre, sobre libre acceso a las actividades de servicios y su ejercicio, y a la Ley 25/2009, de 22 de diciembre, de modificación de diversas leyes para su adaptación a la Ley de libre acceso a actividades de servicios y su ejercicio. (El Capítulo V modifica parcialmente el Real Decreto 178/2004).
- Orden ARM/2616/2010, por la que se establece la composición y funcionamiento del Comité de Participación en el marco del Consejo Interministerial de Organismos Modificados Genéticamente.
- Reglamentos internos de la Comisión Nacional de Bioseguridad, del Comité de Participación y del Consejo Interministerial de Organismos Modificados Genéticamente.
Por otro lado, las Comunidades Autónomas han desarrollado igualmente las competencias que les atribuye la Ley 9/2003 y han elaborado normas que complementan a las mencionadas anteriormente. Esta normativa se puede encontrar en la página Web del Ministerio de Agricultura, Alimentación y Medio Ambiente:
http://www.magrama.gob.es/es/calidad-y-evaluacion-ambiental/temas/biotecnologia/organismos-modificados-geneticamente-omg-/legislacion-general/Legislacion_espaniola.aspx
Finalmente, existe normativa horizontal que no es específica de la seguridad de la biotecnología pero que hay que tener en cuenta a la hora de la comercialización y liberación de organismos modificados genéticamente, así como la normativa sobre los efectos medioambientales derivados de los daños que pudieran ocasionar los Organismos Vivos Modificados. Dentro de esta normativa se encuentra:
- Ley 26/2007, de 23 de octubre, de Responsabilidad Medioambiental.
- Ley 27/2006, de 18 de julio, por la que se regulan los derechos de acceso a la información, de participación pública y de acceso a la justicia en materia de medio ambiente.
- Orden ARM/1783/2011, de 22 de junio, por la que se establece el orden de prioridad y el calendario para la aprobación de las órdenes ministeriales a partir de las cuales será exigible la constitución de la garantía financiera obligatoria, previstas en la disposición final cuarta de la Ley 26/2007, de 23 de octubre, de Responsabilidad Medioambiental.
Además en España, como Estado Miembro de la Unión Europea, es de aplicación la normativa comunitaria, la cual ha sido recogida en el Informe Nacional de la Unión Europea. 
Article 5 - Pharmaceuticals
22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?
  • Yes
23. If you answered Yes to question 22, has this information been submitted to the BCH?
  • Yes
24. Here you may provide further details on the implementation of Article 5 in your country:
ES
Véase el Informe Nacional de la Unión Europea
Article 6 – Transit and Contained use
25. Does your country regulate the transit of LMOs?
This question is relevant to indicator 1.8.1 of the Strategic Plan
  • Yes
26. Does your country regulate the contained use of LMOs?
This question is relevant to indicators 1.1.2 and 1.8.2 of the Strategic Plan
  • Yes
27. If you answered Yes to questions 25 or 26, has this information been submitted to the BCH?
  • Yes
28. Here you may provide further details on the implementation of Article 6 in your country:
ES
El tránsito de organismos vivos modificados queda regulado por el instrumento de ratificación del Protocolo de Cartagena y las actividades de uso confinado se encuentran reguladas por la Ley 9/2003, de 25 de abril, por la que se establece el régimen jurídico de la utilización confinada, liberación voluntaria y comercialización de organismos modificados genéticamente y por el Real Decreto 178/2004, por el que se aprueba el Reglamento general para el desarrollo y ejecución de dicha ley.
Además en España, como Estado Miembro de la Unión Europea, es de aplicación la normativa comunitaria, el Reglamento 1946/2003, de 15 de julio de 2003, relativo al movimiento transfronterizo de organismos modificados genéticamente, con el objetivo de garantizar la aplicación coherente de las disposiciones del Protocolo de Cartagena en la UE. Establece normas para el tránsito de los OVM y para el movimiento transfronterizo de OVM destinados a la utilización confinada, de conformidad con lo dispuesto en el Protocolo de Cartagena. En función del uso del OVM tendrá que cumplir diferentes requisitos. Esto ya ha sido recogido en el Informe Nacional de la Unión Europea.
Articles 7 to 10 – Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment
29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol OR a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment?
This question is relevant to indicators 1.1.2 and 3.1.4 of the Strategic Plan
  • Yes
30. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment?
  • Yes
31. If you answered Yes to question 30, does the mechanism also apply to cases of intentional introduction of LMOs into the environment that were not subject to transboundary movement?
  • Yes
32. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?
  • Yes
33. Has your country established legal requirements for the accuracy of information contained in the notification?
  • Yes
34. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
This question is relevant to indicator 1.1.4 of the Strategic Plan
  • Yes
35. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
This question is relevant to indicator 1.1.5 of the Strategic Plan
  • Yes
36. If you answered Yes to question 35, how many LMOs has your country approved to date for import for intentional introduction into the environment?
  • More than 10
37. If you answered Yes to question 35, how many LMOs, not imported, has your country approved to date for intentional introduction into the environment?
  • More than 10
38. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • More than 10
39. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • More than 10
40. With reference to the decisions taken on intentional transboundary movements of LMOs for intentional introduction into the environment, has your country received a notification from the Party(ies) of export or from the exporter(s) prior to the transboundary movement?
  • Yes
41. Did the notifications contain complete information (at a minimum the information specified in Annex I of the Cartagena Protocol on Biosafety)?
  • Yes
42. Has your country acknowledged receipt of the notifications to the notifier within ninety days of receipt?
  • No
43. Has your country informed the notifier(s) and the BCH of its decision(s)?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • Yes, always
44. What percentage of your country’s decisions fall into the following categories?
  • No aplicable
100%
45. In cases where your country approved an import with conditions or prohibited an import, did it provide reasons on which its decisions were based to the notifier and the BCH?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • Yes, always
46. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment
ES
España aplica la legislación comunitaria y nacional para la autorización de organismos vivos modificados para la liberación al medio ambiente, ya sea con fines experimentales o de comercialización, legislación que se ajusta a las disposiciones del Protocolo, estableciendo un marco reglamentario nacional compatible con el Protocolo, según art. 9.3 del mismo.
La Ley 9/2003 especifica que las competencias de la Administración General del Estado y de las Comunidades Autónomas sobre las autorizaciones de los ensayos experimentales y de liberaciones al medio ambiente. El órgano colegiado de la Administración General del Estado que otorga las autorizaciones es el Consejo Interministerial de Organismos Modificados Genéticamente, el cual es asesorado por un órgano colegiado de carácter técnico, la Comisión Nacional de Bioseguridad.
Al respecto de la pregunta 43, España de actualiza  los registros sobre las decisiones y las evaluaciones de riesgo asociadas con la finalidad de facilitarlas al Centro de Intercambio de la Información de la Seguridad de la Biotecnología. No obstante, tenemos diferentes autoridades competentes en función del uso final de los OVM, por lo tanto, esta información se somete a diferentes agencias gubernamentales. La recopilación de esta información puede dar lugar a algún  retraso de transferencia de información ya que es un proceso lento.
Véase el informe nacional de la Unión Europea.

Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)
47. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?
This question is relevant to indicator 1.1.2 of the Strategic Plan
  • Yes
48. Has your country established legal requirements for the accuracy of information to be provided by the applicant?
  • Yes
49. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • Yes
50. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?
This question is relevant to indicator 1.1.2 of the Strategic Plan
  • Yes
51. Has your country indicated its needs for financial and technical assistance and capacity-building in respect of LMOs-FFP?
This question is relevant to indicator 1.2.1 of the Strategic Plan
  • No
52. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?
  • No
58. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP
ES
España ha sido ponente de varias solicitudes de autorización de Organismos Modificados Genéticamente para la comercialización como alimento humano, pienso y/o para procesado (algunas de las cuales se encuentran pendientes de resolución) y publicó la resolución de autorización del 18 de octubre de 2004, para la importación y procesado de maíz NK603 después de ser aprobado tras el proceso de autorización comunitario (Decisión de la Comisión, de 19 de julio de 2004 relativa a la comercialización, de conformidad con la Directiva 2001/18/CE del Parlamento Europeo y del Consejo, de un tipo de maíz, Zea mays L., línea NK603. DOCE L 295, 18.9.2004) modificado genéticamente para hacerlo resistente al herbicida glifosato, siendo el país ponente de la solicitud.
El Real Decreto 178/2004 por el que se regula el reglamento de aplicación de la Ley 9/2003 relativa a las actividades con OMG en España, en su capítulo III regula la comercialización de organismos modificados genéticamente como productos o como componente de productos, incluyendo el procedimiento de autorización, la evaluación de riesgo, régimen de autorización, o la cláusula de salvaguardia entre otros aspectos.
Además, son de aplicación directa todos los Reglamentos comunitarios aprobados sobre alimentos y piensos modificados genéticamente (Reglamento (CE) Nº 1829/2003), movimientos transfronterizos (Reglamento (CE) Nº 1946/2003) y trazabilidad y etiquetado de Organismos Modificados Genéticamente y trazabilidad de productos producidos a partir de Organismos Modificados Genéticamente (Reglamento (CE) Nº 1830/2003) y los métodos de muestreos y análisis para el control oficial de los piensos al respecto de la presencia de material modificado genéticamente cuya autorización está pendiente o ha expirado (Reglamento (CE) Nº 619/2011.
Article 12 – Review of decision
59. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?
  • Yes
60. Has your country ever received a request for a review of a decision?
  • No
61. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?
  • No
62. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?
  • None
66. Here you may provide further details on the implementation of Article 12 in your country
ES
Sin comentarios
Article 13 – Simplified procedure
67. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?
  • Yes
68. Has your country ever applied the simplified procedure?
  • No
70. In the current reporting period, how many LMOs has your country applied the simplified procedure to?
  • None
71. Here you may provide further details on the implementation of Article 13 in your country
ES
Sin comentarios
Article 14 – Bilateral, regional and multilateral agreements and arrangements
72. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?
  • No
76. Here you may provide further details on the implementation of Article 14 in your country
ES
Véase el informe nacional de la Unión Europea
Articles 15 & 16 – Risk Assessment and Risk Management
77. Has your country established a national framework for conducting risk assessments prior to taking decisions regarding LMOs?
  • Yes
78. If you answered Yes to question 77, does this framework include procedures for identifying and/or training national experts to conduct risk assessments?
  • Yes
79. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs?
This question is relevant to indicator 2.2.3 of the Strategic Plan
a) Risk assessment:
  • 50 or more
b) Management / Control:
  • 10 or more
c) Monitoring:
  • 10 or more
80. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • Yes
81. Is your country using the "Manual on Risk Assessment of LMOs" (developed by CBD Secretariat) for training in risk assessment?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • Yes
82. Is your country using the "Guidance on Risk Assessment of LMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for training in risk assessment?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • Yes
83. Are the currently available training materials or technical guidance on risk assessment and/or risk management of LMOs sufficient?
This question is relevant to indicator 2.2.6 of the Strategic Plan
  • Yes
84. Does your country have the capacity to detect, identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?
This question is relevant to indicators 1.4.2 and 1.6.3 of the Strategic Plan
a) Detect:
  • Yes
b) Identify:
  • Yes
c) Assess:
  • Yes
d) Monitor:
  • Yes
85. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?
This question is relevant to indicators 1.3.1 of the Strategic Plan
a) Risk assessment:
  • Yes
b) Risk management:
  • Yes
86. Is your country using the "Guidance on Risk Assessment of LMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • Yes
87. Has your country adopted any common approaches to risk assessment with other countries?
This question is relevant to indicator 1.3.2 of the Strategic Plan
  • Yes
88. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
This question is relevant to indicator 1.4.1 of the Strategic Plan
  • Yes
89. Has your country ever conducted a risk assessment of an LMO including any type of risk assessment of LMOs, e.g. for contained use, field trials, commercial purposes, direct use as food, feed, or for processing?
This question is relevant to indicator 1.3.3 of the Strategic Plan
  • Yes
90. If you answered Yes to question 89, please indicate the scope of the risk assessments (select all that apply):
  • Commercial production
  • Field trial
  • LMOs for Contained use
  • LMOs for direct use as food
  • LMOs for direct use as feed
  • LMOs for processing
91. If you answered Yes to question 89, were the summary reports of the risk assessments submitted to the BCH?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • Yes, always
92. If you answered Yes to question 89, were risk assessments conducted for all decisions taken on LMOs for intentional introduction into the environment or on domestic use of LMOs for direct use as food, feed, or for processing?
  • Yes, always
93. If you answered Yes to question 89, how many risk assessments were conducted in the current reporting period?
  • More than 10
94. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?
  • Yes
95. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?
  • Yes
96. Does your country have the infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs?
This question is relevant to indicator 2.2.4 of the Strategic Plan
  • Yes
97. Here you may provide further details on the implementation of Articles 15 and 16 in your country
ES
España ha implantado en el marco de la legislación europea y nacional, los procedimientos de evaluación del riesgo para la salud y el medio ambiente de todas las actividades que se llevan a cabo con Organismos Vivos Modificados. Los criterios para dicha evaluación se desarrollan en la Directiva 2001/18/CE y otras Decisiones del Consejo y de la Comisión Europea, así como en las normas nacionales,  la Ley 9/2003 y el Real Decreto 178/2004.
Respecto ala pregunta 91, los informes de evaluación de riesgo se suministran al Centro de intercambio de Información en cuanto se recopila toda la información necesaria y se someten a todas las autoridades implicadas en el proceso, lo cual supone ciertos retrasos.
(Véase también el informe nacional de la Unión Europea).
Article 17 – Unintentional transboundary movements and emergency measures
98. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs?
  • Yes
99. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity?
  • Yes
100. Does your country have the capacity to take appropriate measures in the event that an LMO is unintentionally released?
This question is relevant to indicator 1.8.3 of the Strategic Plan
  • Yes
101. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction?
  • Never
105. Here you may provide further details on the implementation of Article 17 in your country
ES
Véase el Informe Nacional de la Unión Europea
Article 18 – Handling, transport, packaging and identification
106. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?
  • Yes
107. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
This question is relevant to indicator 1.6.1 of the Strategic Plan
  • Yes
108. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
This question is relevant to indicator 1.6.1 of the Strategic Plan
  • Yes
109. If you answered Yes or Yes, to some extent to question(s) 107 and/or 108, what type of documentation does your country require for the identification of LMOs-FFP?
  • Existing types of documentation
110. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?
This question is relevant to indicator 1.6.2 of the Strategic Plan
  • Yes
111. If you answered Yes or Yes, to some extent to question 110, what type of documentation does your country require for the identification of LMOs that are destined for contained?
  • Existing types of documentation
112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?
This question is relevant to indicator 1.6.2 of the Strategic Plan
  • Yes
113. If you answered Yes or Yes, to some extent to question 112, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment?
  • Existing types of documentation
114. Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms?
This question is relevant to indicator 1.6.4 of the Strategic Plan
  • Yes
115. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?
  • Yes
116. How many customs officers in your country have received training in the identification of LMOs?
This question is relevant to indicator 2.3.1 of the Strategic Plan
  • 100 or more
117. Has your country established procedures for the sampling and detection of LMOs?
  • Yes
118. How many laboratory personnel in your country have received training in detection of LMOs?
This question is relevant to indicator 2.3.1 of the Strategic Plan
  • 10 or more
119. Does your country have reliable access to laboratory facilities for the detection of LMOs?
This question is relevant to indicator 2.3.2 of the Strategic Plan
  • Yes
120. How many laboratories in your country are certified for LMO detection?
This question is relevant to indicator 2.3.3 of the Strategic Plan
  • One or more
121. How many of the certified laboratories in the previous question are currently operating in the detection of LMOs?
This question is relevant to indicator 2.3.4 of the Strategic Plan
  • One or more
122. Here you may provide further details on the implementation of Article 18 in your country:
ES
La Unión Europea ha establecido un marco legal sobre Organismos Modificados Genéticamente en los cuales se recoge las medidas que los notificadores han de tomar al respecto de la manipulación, transporte, envasado e identificación. (Véase informe nacional de la Unión Europea).
Dentro de la normativa española específica sobre organismos modificados genéticamente, se exige incluir en la solicitud de autorización una propuesta de etiquetado y envasado donde se indique "Este producto contiene organismos modificados genéticamente".
De igual forma son de aplicación las normas sobre etiquetado y trazabilidad establecidas en la legislación europea.
Article 19 – Competent National Authorities and National Focal Points
123. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?
  • Not applicable
124. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?
  • Yes
125. Here you may provide further details on the implementation of Article 19 in your country
ES
España ha aportado al Centro de Intercambio de la Información sobre la Seguridad de la Biotecnología (CIISB) la información sobre el punto focal nacional para el Protocolo de Cartagena, así como del CIISB.
Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)
126. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH.
This question is relevant to indicator 3.1.5 of the Strategic Plan
a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))
  • Information available and in the BCH
b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)
  • Information available and in the BCH
c) Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))
  • Information not available
d) Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))
  • Information available and in the BCH
e) Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))
  • Information available and in the BCH
f) Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)
  • Information available and in the BCH
g) Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)
  • Information not available
h) Illegal transboundary movements of LMOs (Article 25, paragraph 3)
  • Information not available
i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))
  • Information available and in the BCH
j) Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)
  • Information available and in the BCH
k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)
  • Information available and in the BCH
l) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))
  • Information available and in the BCH
m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)
  • Information available and in the BCH
n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)
  • Information not available
o) LMOs granted exemption status by each Party (Article 13, paragraph 1)
  • Information not available
p) Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)
  • Information not available
q) Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))
  • Information available and in the BCH
127. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?
  • Yes
128. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?
  • Yes
129. Does your country use the information available in the BCH in its decision making processes on LMOs?
  • Yes, always
130. Has your country experienced difficulties accessing or using the BCH?
This question is relevant to indicator 4.1.8 of the Strategic Plan
  • No
131. Is the information submitted by your country to the BCH complete and up-to date?
  • Yes
132. Please indicate the number of regional, national and international events organized in relation to biosafety (e.g. seminars, workshops, press conferences, educational events, etc.,) in the last 2 years:
This question is relevant to indicator 4.3.1 of the Strategic Plan
  • 5 or more
133. Please indicate the number of biosafety related publications that has been made available in your country in the last year:
This question is relevant to indicator 4.3.2 of the Strategic Plan
  • 10 or more
134. If biosafety related publications were made available (see question above), please indicate which modalities were preferred:
This question is relevant to indicator 4.3.2 of the Strategic Plan
  • National Libraries
135. Here you may provide further details on the implementation of Article 20 in your country
ES
España ha designado a la Subdirección General de Medios de Producción Agrícolas y OEVV del Ministerio de Agricultura, Alimentación y Medio Ambiente, como punto focal del Centro de Intercambio de Información de la Seguridad de la Biotecnología.
Por otro lado, España recoge dentro del Portal Web del Ministerio la información más relevante sobre organismos modificados genéticamente que se puede consultar en el siguiente enlace:
http://www.magrama.gob.es/es/calidad-y-evaluacion-ambiental/temas/biotecnologia/organismos-modificados-geneticamente-omg-/
Article 21 – Confidential information
136. Has your country established procedures to protect confidential information received under the Protocol?
  • Yes
137. Does your country allow the notifier to identify information that is to be treated as confidential?
  • Yes, always
138. Here you may provide further details on the implementation of Article 21 in your country
ES
Los titulares de las actividades reguladas por la Ley 9/2003 que proporcionen información a la Administración podrán invocar el carácter confidencial de determinados datos e informaciones facilitados, aportando la justificación correspondiente. La Administración determinará sobre la confidencialidad solicitada y se abstendrá de facilitar la información a terceros sobre los datos e informaciones a los que reconozca dicho carácter. No se podrá considerar información confidencial las informaciones y datos relativos a la descripción de organismos modificados genéticamente, a la identificación del titular, a la finalidad y al lugar de la actividad, a la clasificación del riesgo de la actividad de utilización confinada y a las medidas de confinamiento, a los sistemas y medidas de emergencia y control y a la evaluación de los efectos para la salud humana y el medio ambiente.
Además, se pondrán a disposición del público la información relativa a las liberaciones voluntarias realizadas, las autorizaciones de comercialización otorgadas, la relación de los organismos modificados genéticamente cuya comercialización haya sido autorizada o rechazada como productos o componentes de productos, los informes de evaluación, los resultados de los controles sobre comercialización y los dictámenes de los comités científicos consultados, especificando para cada producto los organismos modificados genéticamente que contenga y sus usos.  
Article 22 – Capacity-building
139. Does your country have predictable and reliable funding for building capacity for the effective implementation of the Protocol?
This question is relevant to indicator 1.2.6 and 3.1.8 of the Strategic Plan
  • No
140. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • No
142. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
143. If you answered Yes to question 142, how were these resources made available?
  • Regional channels
144. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?
  • No
147. During the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
148. If you answered Yes to question 147, in which of the following areas were these activities undertaken?
  • Institutional capacity
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Identification of LMOs, including their detection
  • Implementation of the documentation requirements under Article 18.2 of the Protocol
  • Scientific biosafety research relating to LMOs
149. During the current reporting period, has your country carried out a capacity-building needs assessment?
This question is relevant to indicator 1.2.1 of the Strategic Plan
  • No
151. Does your country still have capacity-building needs?
This question is relevant to indicator 1.2.7 of the Strategic Plan
  • No
153. Has your country developed a capacity-building strategy or action plan?
This question is relevant to indicator 1.2.2 of the Strategic Plan
  • No
154. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?
This question is relevant to indicator 1.2.4 of the Strategic Plan
  • No
155. How many biosafety short-term training programmes and/or academic courses are offered annually in your country?
This question is relevant to indicator 1.2.3 of the Strategic Plan
  • 1 per year or more
156. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?
  • Yes
157. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds
ES
España ha organizado varios seminarios en materia de bioseguridad a traves de la Agencia Española de Cooperación Internacional y Desarrollo y ha aportado la información al Centro de Intercambio de Información de la Seguridad de la Biotecnología.
Por otro lado, España ha aportado fondos para la realización de seminarios y talleres en materia de bioseguridad facilitando la información a la Secretaria del Convenio.
Adicionalmente, España ha participado como docente en la realización de varios cursos, seminarios, talleres y programas de intercambio de información destacando la participación en las actividades sobre bioseguridad desarrolladas dentro del Programa de Asistencia Técnica y de Intercambio de Información de la Dirección General de Ampliación de la Comisión Europea
Article 23 – Public awareness and participation
158. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • Yes
159. Has your country designed and/or implemented an outreach/communication strategy on biosafety?
This question is relevant to indicator 5.3.2 of the Strategic Plan
  • No
160. Does your country have any awareness and outreach programmes on biosafety?
This question is relevant to indicator 5.3.1 of the Strategic Plan
  • No
161. If you answered Yes to question 160, please indicate what entity is responsible for carrying out the programmes and/or services and at which level the programmes take place (e.g. local, national, etc.):
This question is relevant to indicator 5.3.1 of the Strategic Plan
ES
No aplicable
162. Has your country established a biosafety website searchable archives, national resource centres or sections in existing national libraries dedicated to biosafety educational materials?
This question is relevant to indicators 2.5.3 and 5.3.3 of the Strategic Plan
  • Yes
163. How many collaborative initiatives (including joint activities) on the Cartagena Protocol and other Conventions and processes has your government established in the last 4 years?
This question is relevant to indicator 5.2.1 of the Strategic Plan
  • None
164. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?
  • Yes
165. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?
This question is relevant to indicator 2.5.1 of the Strategic Plan
  • Yes
166. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?
This question is relevant to indicator 2.5.1 of the Strategic Plan
  • Yes
167. Has your country informed the public about existing modalities for public participation in the decision-making process regarding living modified organisms?
This question is relevant to indicator 2.5.2 of the Strategic Plan
  • Yes
168. If you answered Yes to question 167, please indicate the modalities used to inform the public:
This question is relevant to indicator 2.5.2 of the Strategic Plan
  • National website
169. If you indicated more than one modality for public participation in question 168, which one was most used?
This question is relevant to indicator 2.5.2 of the Strategic Plan
  • National website
170. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?
  • Yes
171. How many academic institutions in your country are offering biosafety education and training courses and programmes?
This question is relevant to indicator 2.7.1 of the Strategic Plan
  • 5 or more
172. Please indicate the number of educational materials and/or online modules on biosafety that are available and accessible to the public in your country:
This question is relevant to indicators 2.7.2 and 5.3.4 of the Strategic Plan
  • 5 or more
173. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • Yes
174. If you answered Yes to question 173, has your country cooperated with other States and international bodies?
  • Yes
175. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?
  • More than 5
176. Here you may provide further details on the implementation of Article 23 in your country
ES
Según lo dispuesto en la normativa de la Unión Europea y la normativa nacional, todas las solicitudes de liberación voluntaria y de comercialización de OMG, así como algunas solicitudes de utilización confinada deben someterse a un periodo de información pública
En lo que respecta a las notificaciones de liberación voluntaria y utilización confinada, sometidas en España a información pública durante un plazo de 30 días, pueden consultarse en la página Web del Ministerio de Agricultura, Alimentación y Medio Ambiente.
Además, el Ministerio dispone en su página Web de una sección dedicada a la biotecnología en la que se incluye toda la información relativa a los órganos de evaluación de riesgo y toma de decisiones, así como a las solicitudes y comunicaciones presentadas.
Por otro lado, se procede a dar respuesta a las diferentes consultas realizadas a través de los Servicios de Información y Atención al ciudadano de este Ministerio.
En materia de participacion, España dispone de la Ley 27/2006, de 18 de julio, por la que se regulan los derechos de acceso a la información, de participación pública y de acceso a la justicia en materia de medio ambiente que incorpora las Directivas 2003/4/CE y 2003/35/CE (Véase informe de la Unión Europea). La Ley recoge el reconocimiento de los derechos de acceso a la información, de participación y de acceso a la justicia.
Dentro de la regulación específica del derecho de acceso a la información ambiental, la ley establece las obligaciones Administraciones Públicas a informar a los ciudadanos sobre los derechos que les reconoce la Ley y a ayudarles en la búsqueda de la información. Además, para evitar y prevenir daños en caso de amenaza inminente para la salud humana o el medio ambiente, deberá difundirse la información que permita adoptar las medidas necesarias para paliar o prevenir el daño.
Además, la Ley pretende facilitar la obtención de información solicitada que obre en poder de la autoridad a la que se ha dirigido una solicitud. También, establece la regulación de las excepciones a la obligación de facilitar la información ambiental ya que la autoridad pública deberá ponderar en cada caso los intereses públicos y justificar la negativa a suministrar la información solicitada.
Por otro lado, la Ley se ocupa del derecho de participación pública en los asuntos de carácter ambiental en relación con la elaboración, revisión o modificación de determinados planes, programas y disposiciones de carácter general. En este punto, la Ley busca velar por el cumplimiento de una serie de garantías tales como:
• hacer públicamente accesible la información medioambiental relevante
• informar del derecho a participar y de la forma en la que lo pueden hacer
• reconocer el derecho a formular observaciones y comentarios en aquellas fases iniciales del procedimiento
• justificar la decisión finalmente adoptada y la forma en la que se ha desarrollado el trámite de participación
España también ha  ratificado el Convenio de Aarhus (diciembre de 2004), entrando en vigor el 31 de marzo de 2005. El Convenio de Aarhus parte del principio para que los ciudadanos puedan disfrutar del derecho a un medio ambiente saludable y puedan respetarlo y protegerlo, deben tener acceso a la información medioambiental relevante, deben estar legitimados para participar en los procesos de toma de decisiones de carácter ambiental y deben tener acceso a la justicia cuando tales derechos les sean negados. El Convenio ha sido integrado dentro del marco legislativo español.
Al respecto de los Organismos Genéticamente Modificados, España ha aprobado la Orden ARM/2616/2010, por la que se establece la composición y funcionamiento del Comité de Participación en el marco del Consejo Interministerial de Organismos Modificados Genéticamente (CIOMG), a través del cual se pretende asegurar la participación e información pública acerca de la actuación del CIOMG, además de consolidar una vía de comunicación permanente entre la Administración General del Estado y los ciudadanos en las materias que son responsabilidad del mismo. En este sentido, Comité de Participación podrá formular al CIOMG cuantas cuestiones estime oportunas, además de aportar su punto de vista sobre cualquier cuestión relacionada con los organismos modificados genéticamente.
Article 24 – Non-Parties
177. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?
  • No
178. Has your country ever imported LMOs from a non-Party?
  • Yes
179. Has your country ever exported LMOs to a non-Party?
  • No
180. If you answered Yes to questions 178 or 179, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety?
  • Yes
181. If you answered Yes to questions 178 or 179, was information about these transboundary movements submitted to the BCH?
  • Yes, always
183. Here you may provide further details on the implementation of Article 24 in your country:
ES
España importa soja (harina, cascarilla etc.) y maíz transgénico de países no Partes del Protocolo (Argentina, Estados Unidos, etc.). En general se ha comprobado que en la importación de Organismos Vivos Modificados se transmite información de que el producto contiene Organismos Vivos Modificados.
Se realizan controles en los Puestos de Inspección Fronteriza (PIF), de competencia regional en España, y donde todavía hay dificultades en la interpretación y aplicación de las normas de trazabilidad y etiquetado dependiendo de si la importación es de los Organismos Vivos Modificados o de productos obtenidos o derivados de éstos.
Por otro lado, y bajo los controles llevados a cabo por los laboratorios de control oficiales de los Ministerios de Sanidad y Consumo y el de Agricultura, Aliemntacion y Medio Ambiente se efectúan tomas de muestras de semillas y productos para alimentación animal y humana en fronteras y se hacen análisis cuantitativos y cualitativos para detectar una posible presencia adventicia o accidental de Organismos Vivos Modificados.
Article 25 – Illegal transboundary movements
184. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?
  • Yes
185. Has your country established a strategy for detecting illegal transboundary movements of LMOs?
  • Yes
186. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?
If you replied Never to question 186 please go to question 191
  • Never
191. Here you may provide further details on the implementation of Article 25 in your country
ES
Durante el periodo de presentación de informes, en España no se ha registrado ningún movimiento ílicito.
Dentro de la normativa nacional sobre organismos modificados genéticamente, existe un régimen sancionador aplicable a la realización de actividades sin la debida autorización administrativa (Capitulo II del Título IV de la Ley 9/2003).
Por otro lado, la Ley 26/2007, de 23 de octubre, de Responsabilidad Medioambiental recoge en su capitulo III las medidas de prevención, evitación y reparación de daños medioambientales que las Administraciones pueden realizar en caso de un movimiento ílicito.
Article 26 – Socio-economic considerations
192. Does your country have any specific approaches or requirements that facilitate how socio-economic considerations should be taken into account in LMO decision making?
This question is relevant to indicator 1.7.2 of the Strategic Plan
  • No
193. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?
  • Yes
194. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socio-economic considerations?
This question is relevant to indicator 1.7.1 of the Strategic Plan
  • One or more
195. What is your country's experience, if any, in taking socio-economic considerations into account in LMO decision making? Please give details:
This question is relevant to indicator 1.7.3 of the Strategic Plan
ES
Experiencia positiva, se resume en el documento publicado por el Joint Research Centre: "Adoption and Impact of the First GM Crop Introduced in EU Agriculture: Bt Maize in Spain"
196. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs?
  • Yes
197. Here you may provide further details on the implementation of Article 26 in your country
ES
A la hora de adoptar las decisiones en materia de importación de OMG se tiene en cuenta las implicaciones socieconómicas de estos productos para el sector agroalimentario español. La industria agroalimentaria española es dependiente de materias primas de origen vegetal como el maíz, la soja o la colza procedente de Terceros Países. La mayoría de nuestros socios comerciales fuera de la Unión Europea son países en los que la biotecnología está muy extendida.

Por otro lado, en España se cultivan y comercializan variedades convencionales, modificadas genéticamente y destinadas a la producción ecológica sin que hasta la fecha se hayan detectado oficialmente problemas de coexistencia. La Asociación Nacional de Obtentores Vegetales (ANOVE) adjunta con las semillas de variedades modificadas una Guía Técnica y de Buenas Prácticas para el cultivo, en la cual se recogen las recomendaciones de cultivo, así como las medidas de coexistencia y las obligaciones para la prevención de resistencias. El impacto socieconómico del cultivo de maíz MG en España se ha analizado en diferentes estudios científicos, algunos con participación del Joint Research Centre y se ha constatado que los agricultores de las zonas afectadas por la plaga de taladro eligen semillas con el evento MON 810 porque mejoran sus rendimientos productivos.

En cuanto a la cooperación en materia de intercambio de información sobre los efectos socioeconómicos de lo OVM, España participa activamente en las actividades realizadas por el Bureau de consideraciones socioeconómicas del Joint Research para desarrollar documentos guía que permitan determinar los efectos socioeconómicos del cultivo de OMG.

Para finalizar, recientemente se adoptado en la UE,  la Directiva 2015/412 establece que los EEMM podrán adoptar medidas nacionales de prohibición del cultivo con fines comerciales alegando razones de carácter socieconómico.

En Europa, el único cultivo con fines comerciales autorizados es el maíz MON 810. España es el país con la mayor superficie cultivada en la UE (aproximadamente el 90% del total). 
Desde su autorización, la superficie cultivada con maiz MG en nuestro país ha seguido una tendencia generalmente ascendente, con un valor un máximo en el año 2013, en el que casi se alcanzaron las 137 mil hectáreas.  En el año 2014, el número de hectáreas se redujo aproximadamente un 4% con respecto a la de 2013, con una superficie estimada de siembra de 131.537,67 hectáreas. En este año, la superficie total cultivada de maíz (convencional, modificado genéticamente y ecológico) fue de 449.497 hectáreas, reduciéndose también un 4,7% con respecto a la del año 2014. El maiz MG  supone un 20 % aproximado del cultivo de maíz de España, por lo que podemos indicar que el impacto del cultivo actual de los organismos modificados genéticamente en los ingresos de los agricultores en general varía por regiones. Si puede tener importancia en determinadas comarcas donde el taladro es una plaga como Aragón y Cataluña en las que la superficie del cultivo de maíz modificado es elevado.
Article 27 – Liability and Redress
198. Has your country ratified or acceded to the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?
  • Yes
200. Has your country received any financial and/or technical assistance for capacity-building in the area of liability and redress relating to living modified organisms?
This question is relevant to indicator 2.4.1 of the Strategic Plan
  • No
201. Does your country have administrative or legal instrument that provide for response measures for damage to biodiversity resulting from living modified organisms?
This question is relevant to indicators 1.5.2 and 2.4.2 of the Strategic Plan
  • Yes
202. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress
ES
España ha firmado con fecha 21 de julio de 2011 y ratificó en diciembre 2012. 
http://bch.cbd.int/protocol/parties/#tab=1
Article 28 – Financial Mechanism and Resources
203. How much additional funding (in the equivalent of US dollars) has your country mobilized in the last four years to support implementation of the Biosafety Protocol, beyond the regular national budgetary allocation?
This question is relevant to indicator 1.2.5 of the Strategic Plan
  • 500,000 USD or more
Article 33 – Monitoring and reporting
204. Does your country have in place a monitoring and/or an enforcement system for the implementation of the Cartagena Protocol?
This question is relevant to indicator 3.1.6 of the Strategic Plan
a) Monitoring system:
  • Yes
b) Enforcement system:
  • Yes
205. Has your country submitted all the previous due National Reports?
  • Yes
Comments on reporting format
185. Please use this field to provide any other information on difficulties that you have encountered in filling in this report
ES
En la pregunta 42, sobre si se ha acusado recibo al notificador de las notificaciones en un plazo de 90 días desde su recibo, sería interesante incluir una casilla que indique que "No aplicable". Sólo existe una casilla que indica "No", no pudiéndose diferenciar estos casos.

Ocurre igual en las preguntas que hacen referencia a la información aportada al Centro de Intercambio de Infomación de la Seguridad de la Biotecnología (pregunta 126, por ejemplo). En el documento word preparado para recopilar la información of line si incluye una casilla "No aplicable", pero al cumplimentarlo en el formato on line no aparece esta casilla, y solo se puede marcar la opcion "Información no disponible". Seria interesante incluir una casilla para diferenciar los casos en que no se aportado la informacion al Centro de Intercambio de aquellos que la información No existe, y seria "No aplicable". En la actualidad, sólo existe una casilla que indica No disponible, no pudiendose diferenciar estos casos.